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Abstract
Background: Microarray experiments are becoming increasingly common in biomedical research, as is their
deposition in publicly accessible repositories, such as Gene Expression Omnibus (GEO). As such, there has been a
surge in interest to use this microarray data for meta-analytic approaches, whether to increase sample size for a
more powerful analysis of a specific disease (e.g. lung cancer) or to re-examine experiments for reasons different
than those examined in the initial, publishing study that generated them. For the average biomedical researcher,
there are a number of practical barriers to conducting such meta-analyses such as manually aggregating, filtering
and formatting the data. Methods to automatically process large repositories of microarray data into a
standardized, directly comparable format will enable easier and more reliable access to microarray data to conduct
meta-analyses.
Methods: We present a straightforward, simple but robust against potential outliers method for automatic quality
control and pre-processing of tens of thousands of single-channel microarray data files. GEO GDS files are quality
checked by comparing parametric distributions and quantile normalized to enable direct comparison of expression
level for subsequent meta-analyses.
Results: 13,000 human 1-color experiments were processed to create a single gene expression matrix that subsets
can be extracted from to conduct meta-analyses. Interestingly, we found that when conducting a global meta-
analysis of gene-gene co-expression patterns across all 13,000 experiments to predict gene function, normalization
had minimal improvement over using the raw data.
Conclusions: Normalization of microarray data appears to be of minimal importance on analyses based on co-
expression patterns when the sample size is on the order of thousands microarray datasets. Smaller subsets,
however, are more prone to aberrations and artefacts, and effective means of automating normalization
procedures not only empowers meta-analytic approaches, but aids in reproducibility by providing a standard way
of approaching the problem.
Data availability: matrix containing normalized expression of 20,813 genes across 13,000 experiments is available for
download at . Source code for GDS files pre-processing is available from the authors upon request.
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Background
Using microarrays for hypothesis generation and valida-
tion has become routine in virtually every area of biome-
dical research. However, the majority of generated data is
underutilized since publications reporting microarray
results often focus on a small subset of the results they
feel are most relevant to their research focus, even if
other interesting observations may be present in the data.
Thanks to the Minimum Information About a Microar-
ray Experiment (MIAME) [1] to standardize descriptions
and reproducibility, along with the requirement imposed
by most journals to make microarray data publicly acces-
sible, this wealth of data is accessible to the community.
Microarray data repositories, such as Gene Expression
Omnibus (GEO) [2], ArrayExpress [3], Stanford Microar-
ray Database [4] contain growing amounts of gene
expression data from multiple biological organisms and
treatments. For example, besides just storing microarray
data, GEO also provides a simple web interface to analyze
and compare individual GDS (GEO Data Set) files.
ArrayExpress also provides a means to access its database
via ExpressionProfiler software [5] and with Bioconduc-
tor R package for subsequent analysis. However, the abil-
ity to conduct a large-scale meta-analysis focused on a
specific condition or disease, is not provided and neither
is it trivial to compile a list of datasets associated with
such conditions that are directly comparable. One of the
chief concerns is the heterogeneity among probe design
within microarray platforms, laboratory variations, and
methods of data pre-processing.
Whether the meta-analysis is focused on specific
experimental types [6,7] or is aimed at a global assess-
ment of gene expression patterns across all experiments
[8-10], the major hurdle is that it heavily depends on
the quality of the underlying data. For example, if a
probe on one platform hybridizes to a much longer
transcript than on another platform, the probe intensity
will appear constitutively higher and direct comparisons
will suggest differential expression. The accuracy and
reproducibility of commonly used microarray platforms
has been hotly debated with results ranging from rela-
tively discouraging [11,12] to promising [13,14]. A
multi-center consortium, MicroArray Quality Control
(MAQC) performed independent assessment of gene
expression data reproducibility and found results to be
very optimistic [15]. Furthermore, MAQC II analysis
confirmed biological differences as the most readily
detected value [14,16]. However, a human factor (i.e.
people conducting identification of biological differ-
ences) is one of the most important pieces on the analy-
sis [16]. As such, detection of true biological differences
require a comprehensive method of diverse microarray
data integration conducted with an understanding of the
underlying technical and biological issues.
Gene nomenclature poses another serious problem in
comparison of different microarray platforms. Gene
identifiers, such as GenBank, Illumina IDs, Affymetrix
IDs have different underlying annotations and are not
directly comparable. Several attempts have been made
to overcome those hurdles. Two tools, List of lists-anno-
tated (LOLA) [17] and List to List (L2L) [18] were cre-
ated to compare gene lists against microarray data from
different platforms, different nomenclatures, or even dif-
ferent organisms. However, these tools rely on published
data and need to be manually curated. A cancer-
oriented database, ONCOMINE [19], was developed for
queuing gene expression profiles in different tumor
types and tissues. CellMontage allows users to correlate
a custom pre-processed gene expression dataset with
GEO datasets grouped by platforms [20]. M2DB is a
curated microarray database which is designed for easy
quality control and retrieval of raw and normalized
microarray data [21]. A major drawback of these tools is
that they require different input format and produce dif-
ferent results often biased towards particular tissue, plat-
form (CellMontage, M2DB) and/or disease (Oncomine).
Several papers have been published that thoroughly
outline the challenges, opportunities and recommenda-
tions for standardization of microarray meta-analysis,
discussing the benefits and pitfalls, and comparing
methods for data processing [10,22-26]. Rather than
develop a different method, the work reported here is
based on a combination of the recommendations
reported in these studies (e.g., mapping probe IDs to a
unified Entrez identifier). In addition, we consider fun-
damental properties of microarray data distributions
[27,28] to standardize different experimental data for
meta-analysis. We present a straightforward method of
extracting gene expression data from publicly available
datasets, performing quality control of the data, compre-
hensively mapping it to Entrez Gene IDs and creating a
gene expression matrix from multiple experiments. Our
method is based on the use of intrinsic properties of
microarray data, adjusted by quantile normalization to
unify distribution of gene expression across diverse
experiments and to accurately determine a level of tech-
nical noise. We compile a gene expression matrix from
13,000 human 1-color microarray experiments, establish
noise level and make expression values comparable
across datasets. We showed our pre-processing steps
increase recall and precision for prediction analysis.
Methods
Obtaining one-color microarray data
GEO Datasets (GDS) files were downloaded from ftp://
ftp.ncbi.nih.gov/pub/geo/DATA/SOFT/GDS/ and
uncompressed from .gz compression format. Files were
selected for processing if the following fields were
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dataset_sample_organism=“homo sapiens”, dataset_ty-
pe=”nucleotide” or “gene expression”, dataset_channel_-
count=”single” or “1”, and dataset_value_type=”count”.
This ensures only raw data from one-channel human
microarray samples were processed.
Probe mapping
Probe mapping was done using a relational database,
assigning unique Entrez ID identifiers based on gene
names and accession numbers downloaded from NCBI
(ftp://ftp.ncbi.nih.gov/gene/DATA/GENE_INFO/Mam-
malia/Homo_sapiens.gene_info.gz). Unmapped probes
were stored in a file and examined if any of the plat-
forms was unmapped due to absence of its mapping
data in the database. Each technological platform has
unique set of probes targeting different gene regions.
Moreover, some probes recognize particular isoforms of
the same genes, such as implemented in Affymetrix and
Illumina platforms. Affymetrix uses extensions to its
unique IDs, such as “_at” indicating a probe recognizing
a unique gene isoform. “_s_at” extension indicates a
probe can recognize multiple isoforms of the same gene.
Illumina flags its IDs by “I” (a probe recognizes a single
isoform) and “A” (a probe recognizing all isoforms). Due
to aforementioned problems of linking diverse manufac-
turer’s IDs to unique gene identifiers it is logical to use
probes recognizing all isoforms of a given gene. Such
probes should have maximum expression value relative
to other probes that only recognize individual isoforms
of the same gene. Therefore, the maximum expression
value was selected from multiple probes targeting the
same gene.
Data pre-processing
Basic parameters were calculated for each dataset,
namely, mean and median. Datasets with mean or
median equal to 0 were excluded, as well as the data-
sets with mean to median ratio equal to or less than 1
(see Results for explanation). Data for each experiment
were sorted and distribution of expression values
around maximum was examined. Due to technological
imperfections some genes demonstrate extreme satu-
rated measurements at the high end of expression
spectrum. Such expression values would negatively
influence the following quantile normalization step by
introducing artefacts, and should be adjusted. Overall,
no more than 0.1% of maximum expression values
showed extreme measurements. For each experiment,
0.1% of genes with highest expression values were
selected, and a minimum expression value (flooring
value) among them was identified. Expression of these
genes was replaced with this flooring value. Each
experimental dataset was then adjusted to fit within
0 - 10,000 range.
Low expression values in each microarray dataset con-
stitute technical noise that can be approximated with
normal distribution [27]. To make distributions of dif-
ferent datasets equal the data fit within 0-10,000 range
were quantile-normalized [29]. Briefly, quantile normali-
zation replaces distributions of each dataset with an
average distribution, calculated from an average of
sorted expression values across all datasets. This step
does not alter the data structure (see Results for expla-
nation) but makes it possible to define common noise
threshold and directly compare expression level across
the whole matrix.
Validating data preprocessing steps
We explored the data structure in 1) The matrix con-
taining raw expression values; 2) matrix containing
scaled to 0-10,000 range data; and 3) matrix containing
scaled and quantile normalized data. We performed
gene ontology prediction analysis [8] and calculated pre-
cision/recall based on the number of correctly predicted
gene ontologies (Equations 1 and 2). We show our
results in a form of F-measure, a test for accuracy that








A total of 2,325 GDS files were downloaded, out of
which 587 contained raw gene expression data from
human single-channel microarrays. Probe identifiers
were mapped to Entrez IDs, totaling 20,814 genes.
Quality control: mean/median ratio
Single-channel microarray data follows well-defined dis-
tribution that can be approximated with a lognormal
model [27,28]. Genes expressed below noise level form a
pronounced normal distribution at low expression levels
while genes expressed above noise are spread across the
whole spectrum of expression. These properties of
microarray data distribution dictate that its mean and
median parameters can’t be equal, whereby a median
should be always smaller than a mean. Thus, the mean/
median ratio in a dataset should always be more than 1.
Investigation of Mean/Median ratio (MM ratio) in all
datasets proved this to be the case for majority of data-
sets. Median value for MM ratio was 4.55 (Figure 1).
Seven datasets (139 experiments total) with MM ratio
less than or equal to 1.2 were removed as suspects for
bad quality data. A total of 577 datasets with 13,000
experiments were used for further analysis.
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Data re-scaling
While remaining datasets did not contain negative values,
raw expression data distribution may show inconsistent
intensities at very high expression level [30]. Manual
inspection of all datasets for possible outliers identified
on average 0.1% (~20 genes) of the top expression values
showing extreme measurements. Such extreme measure-
ments would distort data rescaling in unpredictable ways.
To minimize the impact of such outliers they were set to
their minimum value (floored). This step included selec-
tion of top 0.1% of genes with highest expression level in
each unprocessed experiment, identifying their minimum
and setting them to that minimum. This change on 0.1%
expression values did not affect data distribution (data
not shown). The resulting matrix of 13,000 experiments
containing expression values for 20,814 genes was scaled
to 0-10,000 range.
Quantile normalization
Gene expression matrix from 13,000 experiments con-
tained data from different experimental platforms. Affyme-
trix platforms delivered highest number of datasets, with
234 datasets done on Affymetrix Human Genome U133A
Array (GPL96) followed by 111 datasets on Affymetrix
Human Genome U95A Array (GPL91) platform (Figure 2).
Even though different platforms yield comparable
experimental results [15], the data from different plat-
forms produced different distributions. That is, the para-
meters of the lognormal model that can be fitted to
them [27,28] differ (Figure 3A). To make them compar-
able we applied quantile normalization [29]. Quantile
normalization only rescales data distributions to make
them fit to an average distribution calculated from all
datasets. An example of data before and after normaliza-
tion is shown in Figure 3.
Figure 1 Frequency histogram of mean/median ratio distribution of datasets used for processing. Datasets with MM ratio less than 1.2
were excluded.
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Distribution after quantile normalization
Data before and after quantile normalization correlated
with each other (Figure 4A), R2=0.99. Quantile-normal-
ized data from all experiments has the same distribution
(Figure 4B) and preserves the rank-order of genes by
expression level in each dataset. A normal distribution
was fitted around the peak of low expressed genes and
its parameters were determined. Mean was determined
to be 36 and standard deviation (SD) was 26. As such,
the noise level threshold, commonly defined as 3 SD
above mean was determined to be 114, above which the
level of gene expression can be detected with 99% accu-
racy. Thus, genes with expression values >114 in the
resulting matrix can be considered expressed with p <
0.01 in any given experiment.
Testing the effect of normalization on predicting gene
function
It is hard to empirically demonstrate the superiority of
one normalization approach over another. It is, however,
important to know if your methods of normalization
had a positive effect. Recently, we described a means of
using a global microarray meta-analysis of gene-gene
co-expression patterns to predict gene function [8]. The
basis for this is successful grouping of gene-gene co-
expression patterns from heterogeneous datasets to
identify gene pairs whose co-expression is strongly cor-
related regardless of the experimental condition. Genes
that have strong correlations across datasets tend to
share similar biological functions. We found the top 20
co-expressed genes (e.g., as judged by the strongest
Figure 2 Platforms and number of datasets used in the current study. A total of 43 platforms were used, which comprised 577 datasets
and 13,000 experiments.
Figure 3 Box-and-whisker plots of data distribution in a sample dataset before (A) and after (B) quantile normalization. X axis – dataset
names, Y axis – expression range, only values in 0-1,000 range shown for clarity.
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Pearson’s correlations) tend to accurately predict the
GO categories of any given gene of interest [8]. As we
report in a related study [31], we find that the predic-
tiveness of these genes rapidly declines the more that
are taken for analysis, suggesting the best accuracy will
result from effectively identifying and grouping the most
correlated genes. Technical noise, however, should affect
the cohesiveness of pairings and, consequently, the pre-
cision by which we can predict biological function. We
hypothesized that raw data should produce more erro-
neous predictions because it is noisier and contains dis-
tortions within the data distributions that should affect
accurate measurement. Thus, if the normalization
scheme is effective and biologically relevant, it should
increase the accuracy by which gene function can be
predicted on the basis of global co-expression patterns
in raw data.
To test this, we conducted a global meta-analysis to
predict GO categories. 16,140 genes with known GO
categories were used for analysis. The most highly cor-
related genes in terms of their co-expression patterns
across all 13,000 microarrays were identified using
metrics described in a related work [31]. For each gene,
its top 20 genes were used to predict it’s GO category.
The results were compared against its annotated GO
category, looking for the fraction of predicted categories
that were exact matches to the annotated categories. In
this analysis we wanted to identify the effects on both
precision (i.e., ability to correctly predict GO categories)
and recall (i.e., ability to find as many known annota-
tions as possible). As such, we used F-measure (defined
as (precision+recall)/2)) to estimate the effect of pre-
processing steps and normalization on predicting gene
functions.
We compared predictions using the raw data, data
that was scaled and outliers eliminated as described, and
data fully normalized as described herein. We found
using the raw data, the F-measure was 0.114. Scaling the
data to a common 0-10,000 range increased the F-mea-
sure to 0.125, and using quantile normalized data
allowed us to reach an F-measure of 0.130. These results
demonstrate that each pre-processing step increases the
ability of the global meta-analysis to identify biologically
relevant patterns of co-expression.
Discussion
One enabling factor for high-throughput data standardi-
zation is that the input data files should have a well-
defined structure for mapping data elements. Specifi-
cally, within GEO, the GDS (GEO dataset) files work
best for that purpose, since they are reassembled by
GEO staff and stored in text files with information
fields. GDS files are standardized versions of the origin-
ally submitted GSE (GEO series) files. GSE datasets lack
a standardized structure and will require manual reas-
sembly, which currently lags the production of such
datasets and is a reason others have chosen to exclude
them as well [10], [32].
One of the primary challenges in standardizing data-
sets is choosing an appropriate identifier for each gene.
Fortunately, many tools exist to convert microarray IDs
between database probe names and among the more
developed are DAVID [33] and RESOURCERER [30].
One dedicated effort, AILUN, attempted to map all
Figure 4 Data distribution before and after quantile normalization. Example of expression changes in a dataset before and after quantile
normalization, and a frequency histogram of an average distribution fit to all datasets. A) Data from a sample dataset plotted before (X-axis) vs.
after (Y-axis) quantile normalization. No major distortions were observed, quantile normalization introduced only transitional rescaling to the
data; B) An average distribution fitted to all datasets. This distribution allows setting global noise threshold and directly comparing expression
levels across the datasets.
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GEO IDs to a unique identifier [34]. Our solution here
was to try to map to a common, widely used identifier,
the Entrez gene IDs [35] (superseding LocusLink) as
defined by NCBI. Entrez’s “one gene – one ID” concept
suits well for the purpose of bringing expression values
from multiple probes targeting one gene to a single pla-
ceholder, the only drawback being that some probes on
lesser used platforms may not map to a gene ID. The
number of such experimental probes varies significantly
from platform to platform. Ultimately, next-generation
sequencing will provide an even bigger challenge for
meta-analysis, as many sequences identified will not
have existing identifiers.
Single-channel microarray data have been shown to
exhibit a well-defined distribution of their values
[27,28]. A frequency histogram of low-expressed values
shows a peak that approximates a normal distribution,
the parameters of which serve as a platform-defined
(and platform-dependent) noise threshold. Expressed
probes are those on the rightmost tail of the distribution
-the highly expressed values. The nature of these experi-
mental data distributions dictates that the mean and
median of the data can’t be equal. Indeed, as shown on
Figure 1, the Mean/Median ratio for the majority of the
datasets differed from 1. This parameter is a quick and
simple estimate of microarray data quality, and should
be included in data quality control.
Data from different technological platforms have dif-
ferent levels of noise and probe intensity and direct
comparisons could be misleading without first correct-
ing for these issues. Quantile normalization [29] is a
means of normalizing data distributions to an averaged
distribution across all datasets. As expected (Figure 4),
an average distribution of all datasets, showed pro-
nounced peak of low-expressed genes, which can be
fitted with normal distribution. Although quantile nor-
malization changed expression values slightly to make
them fit to an average distribution, such changes are
gradual. If a gene is co-expressed with another gene, a
slight change in expression level even of both genes will
not change the fact of their co-expression. Quantile nor-
malization may slightly influence calculation of Pearson
product-moment correlation coefficient, a metric for
estimating correlation between two vectors, although we
do not anticipate it to be a major problem.
Each experimental platform may suffer from erro-
neous or artefactual expression measurements, such as
negative values, or extremely high expression. Since
gene expression can’t be negative, such values, if pre-
sent, should be flagged. In the present study datasets
that passed quality control did not have negative values,
which does not guarantee their absence in other datasets
that could be added to the total pool in the future. We
observed extremely high expression measurements
across several datasets (e.g., where one gene is several
orders of magnitude higher than any other). Such out-
liers may negatively affect performance of quantile nor-
malization by skewing the average distribution in an
unpredictable manner. Therefore, we “floored” top 0.1%
of the data to decrease outliers’ effect. Although this
“flooring” did not noticeably affect co-expression analy-
sis (data not shown) we feel this negligible data treat-
ment is an important precaution against possible
technology-related errors.
To our surprise, even raw data can be used for pre-
dicting gene ontology categories using a global meta-
analysis of all available data [8], although precision and
recall are slightly less than processed data. Closer exami-
nation of the data revealed that even in raw data, gene-
gene co-expression patterns are nonetheless discernable.
This is similar to considering gene ranks [36] which are
also retained in the raw data. Re-scaling the data, how-
ever, allowed more precise predictions to be made, since
common thresholds could be applied. Quantile normali-
zation further increased recall/precision of the predic-
tions, because more exact thresholds can be defined.
This step is imperative for comparative meta-analysis of
data subsets, where absolute level of expression among
different conditions and platforms should be compared.
Conclusions
In this work we addressed potential pitfalls and problems
associated with microarray meta-analysis of large number
of disparate microarray experiments [22] and present
specific steps and precautions. As such, the current paper
aims at providing a means for creating a global, unified
and directly comparable matrix of expression values asso-
ciated with individual microarray experiments. We pro-
vide a framework for researchers to use pre-processed
datasets of interest for their own research.
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